385 related articles for article (PubMed ID: 26309122)
21. New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents.
Tung TT; Oanh DT; Dung PT; Hue VT; Park SH; Han BW; Kim Y; Hong JT; Han SB; Nam NH
Med Chem; 2013 Dec; 9(8):1051-7. PubMed ID: 23521008
[TBL] [Abstract][Full Text] [Related]
22. Quinolone-based HDAC inhibitors.
Balasubramanian G; Kilambi N; Rathinasamy S; Rajendran P; Narayanan S; Rajagopal S
J Enzyme Inhib Med Chem; 2014 Aug; 29(4):555-62. PubMed ID: 25019596
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors.
Routholla G; Pulya S; Patel T; Abdul Amin S; Adhikari N; Biswas S; Jha T; Ghosh B
Bioorg Chem; 2021 Sep; 114():105050. PubMed ID: 34120025
[TBL] [Abstract][Full Text] [Related]
25. Lactam-based HDAC inhibitors for anticancer chemotherapy: restoration of RUNX3 by posttranslational modification and epigenetic control.
Cho M; Choi E; Kim JH; Kim H; Kim HM; Lee JI; Hwang KC; Kim HJ; Han G
ChemMedChem; 2014 Mar; 9(3):649-56. PubMed ID: 24376239
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.
Jiao J; Fang H; Wang X; Guan P; Yuan Y; Xu W
Eur J Med Chem; 2009 Nov; 44(11):4470-6. PubMed ID: 19608304
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and Biological Evaluation of 1-(2-Aminophenyl)-3-arylurea Derivatives as Potential EphA2 and HDAC Dual Inhibitors.
Zhu Y; Ran T; Chen X; Niu J; Zhao S; Lu T; Tang W
Chem Pharm Bull (Tokyo); 2016; 64(8):1136-41. PubMed ID: 27477652
[TBL] [Abstract][Full Text] [Related]
28. Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
Marson CM; Matthews CJ; Yiannaki E; Atkinson SJ; Soden PE; Shukla L; Lamadema N; Thomas NS
J Med Chem; 2013 Aug; 56(15):6156-74. PubMed ID: 23829483
[TBL] [Abstract][Full Text] [Related]
29. Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
Cincinelli R; Musso L; Artali R; Guglielmi M; Bianchino E; Cardile F; Colelli F; Pisano C; Dallavalle S
Eur J Med Chem; 2018 Jan; 143():2005-2014. PubMed ID: 29150335
[TBL] [Abstract][Full Text] [Related]
30. Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity.
Xie R; Li Y; Tang P; Yuan Q
Bioorg Med Chem Lett; 2017 Sep; 27(18):4415-4420. PubMed ID: 28818449
[TBL] [Abstract][Full Text] [Related]
31. Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity.
Gaisina IN; Tueckmantel W; Ugolkov A; Shen S; Hoffen J; Dubrovskyi O; Mazar A; Schoon RA; Billadeau D; Kozikowski AP
ChemMedChem; 2016 Jan; 11(1):81-92. PubMed ID: 26592932
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and antitumor activity evaluation of novel HDAC inhibitors with tetrahydrobenzothiazole as the skeleton.
Sun S; Zhao W; Li Y; Chi Z; Fang X; Wang Q; Han Z; Luan Y
Bioorg Chem; 2021 Mar; 108():104652. PubMed ID: 33497873
[TBL] [Abstract][Full Text] [Related]
33. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
Li X; Hou J; Li X; Jiang Y; Liu X; Mu W; Jin Y; Zhang Y; Xu W
Eur J Med Chem; 2015 Jan; 89():628-37. PubMed ID: 25462271
[TBL] [Abstract][Full Text] [Related]
34. Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
Yang Z; Wang T; Wang F; Niu T; Liu Z; Chen X; Long C; Tang M; Cao D; Wang X; Xiang W; Yi Y; Ma L; You J; Chen L
J Med Chem; 2016 Feb; 59(4):1455-70. PubMed ID: 26443078
[TBL] [Abstract][Full Text] [Related]
35. Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors.
Mohamed MFA; Youssif BGM; Shaykoon MSA; Abdelrahman MH; Elsadek BEM; Aboraia AS; Abuo-Rahma GEA
Bioorg Chem; 2019 Oct; 91():103127. PubMed ID: 31374527
[TBL] [Abstract][Full Text] [Related]
36. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
Ojha R; Huang HL; HuangFu WC; Wu YW; Nepali K; Lai MJ; Su CJ; Sung TY; Chen YL; Pan SL; Liou JP
Eur J Med Chem; 2018 Apr; 150():667-677. PubMed ID: 29567459
[TBL] [Abstract][Full Text] [Related]
37. Discovery of indole-3-butyric acid derivatives as potent histone deacetylase inhibitors.
Chen Y; Zhang L; Zhang L; Jiang Q; Zhang L
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):425-436. PubMed ID: 33445997
[TBL] [Abstract][Full Text] [Related]
38. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
[TBL] [Abstract][Full Text] [Related]
39. Discovery of adamantane based highly potent HDAC inhibitors.
Gopalan B; Ponpandian T; Kachhadia V; Bharathimohan K; Vignesh R; Sivasudar V; Narayanan S; Mandar B; Praveen R; Saranya N; Rajagopal S; Rajagopal S
Bioorg Med Chem Lett; 2013 May; 23(9):2532-7. PubMed ID: 23538115
[TBL] [Abstract][Full Text] [Related]
40. A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities.
Yang F; Peng S; Li Y; Su L; Peng Y; Wu J; Chen H; Liu M; Yi Z; Chen Y
Org Biomol Chem; 2016 Feb; 14(5):1727-35. PubMed ID: 26732459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
